multi-antigen-directed autologous T cells NEXI-002

{
  "id": "MLC-T-ONC-015339",
  "term": "multi-antigen-directed autologous T cells NEXI-002",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms' tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.",
  "synonyms": [
    "autologous MM-associated antigens specific T cells NEXI-002",
    "NEXI-002 T cells",
    "TAA primed antigen-specific CD8+ T cells NEXI-002"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/multi-antigen-directed-autologous-t-cells-nexi-002/"
}